AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02865902 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low-Level Laser Therapy by Ezlase; Biolase®
Description: comparision of the effects of low-level-laser therapy on wound healing of palatal donor site
Study NCT02865902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy by Ezlase; Biolase®
Description: comparision of the effects of low-level-laser therapy on wound healing of palatal donor site
Study NCT03658824 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Behavioural Activation (BA)
Description: BA is based on the assumption that depression may be precipitated and is maintained by a reduction in healthy, adaptive behaviours and positive reinforcement of these, and an increase in avoidance behaviours. Together, these changes reduce the person's immediate distress, often at the expense of their medium and longer term goals. The therapy involves helping the individual to re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours that are constructive in the longer term.~The intervention consists of up to 20 individual therapy sessions of Behavioural Activation, with one booster session three months after the end of therapy. Each session lasts approximately 50 minutes and this is supplemented by home practice between sessions.
Study NCT02658890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Study NCT02658890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02658890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT01209429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH hormone infusion
Description: Norditropin 30 ng/kg/min
Study NCT01209429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 42 hour fast
Description: The participant will be fasting 42 hours prior to the start of the study day, drinking water is allowed
Study NCT01209429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12 hour fast
Description: 12 hour fast will be used as a control scenario to 42 hour fast
Study NCT01209429 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 12 hour fast
Description: 12 hour fast will be used as a control scenario to 42 hour fast
Study NCT04205617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: produce prescription and nutrition education
Description: Participants will receive diabetic appropriate groceries, diabetes education classes led by volunteer doctors and nurses, cooking demonstrations, shared meals, 1:1 and group coaching by dietitians.
Study NCT04787978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity and Education Intervention
Description: The intervention involves peer teams, health coaches and community health workers \[CHW\]. Each participant will be assigned to a CHW and grouped into a team of 10-20 participants based on participant proximity to a Columbus Recreation and Parks Center. Each team will be assigned 4 health coaches, 2 medical students, 1 undergraduate student and 1 nursing student from OSU Health Sciences Colleges.~The lifestyle intervention is 24 weeks consisting of 1 hour and 15 minutes of in person training time per week. The training time consists of 45 minutes of physical activity and 30 minutes of educational content was informed by evidence-based strategies and stakeholder feedback.~Health coaches will implement the curriculum based on the Diabetes Prevention Program and the American Heart Association Check, Change, Control Program and develop team-based SMART (specific, measurable, achievable, relevant, and time-bound) wellness goals.
Study NCT04523883 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: postoperative radiotherapy
Description: postoperative radiotherapy with a dose of 60-66Gy
Study NCT04523883 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: postoperative radiotherapy
Description: postoperative radiotherapy with a dose of 60-66Gy
Study NCT04523883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: JS001 240mg every three week
Study NCT01050244 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole soybean soymilk powder
Study NCT01050244 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Whole milk powder
Study NCT00630435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin®/MPA formulation A
Study NCT00630435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin®/MPA formulation B
Study NCT00630435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin®/MPA formulation C
Study NCT02734888 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No drug or device, only a test. The test is called a PET/CT
Description: A single PET/CT scan will be performed
Study NCT03162874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXT002331 - dose 1
Description: Oral
Study NCT03162874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXT002331 - dose 2
Description: Oral
Study NCT01917682 — intervention group
Intervention type: PROCEDURE
Intervention: CorPath-assisted Percutaneous Coronary Intervention
Description: Robotic-assisted Percutaneous Coronary Intervention
Study NCT00630435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premarin®/MPA currently marketed product
Study NCT03212534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient mortality prediction
Description: Healthcare provider is notified of patient mortality prediction.
Study NCT02587819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with BSCT
Description: The study product BSCT (anti-nf-P2X7) 10% Ointment was anti-nf-P2X7 (highly purified sheep IgG) in an ointment formulation for topical administration. The formulation contained 10% weight by weight of the active pharmaceutical ingredient in an anhydrous ointment base.~Fifty (50) to 100 mg of product (an amount the size of a small pea) was applied topically twice a day for 28 days to a 25 cm2 area of skin containing a single BCC lesion. The product was to be applied in the morning and in the evening after washing.
Study NCT01111955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-823778
Description: Capsules, Oral, 2 mg, once daily, 28 days
Study NCT01111955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-823778
Description: Capsules, Oral, 10 mg, once daily, 28 days
Study NCT01111955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-823778
Description: Capsules, Oral, 20 mg, once daily, 28 days
Study NCT01111955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0 mg, once daily, 28 days
Study NCT01081899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The LCP-I Program
Description: The LCP-I Program is a continuous quality Improvement Program of end-of-life care implemented by a Palliative Care Unit (PCU) in a hospital Medical Ward.
Study NCT03662594 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ECMO
Description: In this project, the investigators will apply a new technique of atomic layer deposition (ALD) to coat biocompatible and hemocompatible ZrO2/Al2O3 nanolaminate thin films on the inner surface of ECMO tubing to suppress the device-induced coagulopathy. ALD is a thin-film deposition technique for preparing high-quality oxides with atomic-layer accuracy. It offers many benefits including accurate thickness control. These characteristic clear accounts of the high-quality hemocompatible oxide thin films on the whole surface of complex 3-D structures, such as the inner surface The newly-prepared ECMO circuit will then undergo in vitro tests and animal study to carefully examine the safety and effectiveness of improvement of hemocompatibility.
Study NCT01111955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Capsules, Oral, ≥ 1500 mg, once daily, 28 days
Study NCT01111955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Capsules, Oral, ≥ 1500 mg, once daily, 28 days
Study NCT04141540 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Molecular analyses
Description: Comparaison of the molecular profil between two monozygotic twins carrying a deletion 22q11.2
Study NCT02760641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg-based diet (EBD)
Description: Participants will be asked to consume a carbohydrate-restricted diet including whole eggs for 8 weeks. Eggs will be provided.
Study NCT02760641 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate-based diet (CBD)
Description: Participants will be asked to consume a low fat, carbohydrate-based diet for 8 weeks. Breakfast food items will be provided.
Study NCT00192413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza vaccine trivalent (CAIV-T)
Description: Liquid CAIV-T vaccine for this study consisted of 3 cold-adapted, attenuated, reassortant strains, representing the HA and NA antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Victoria/504/2000 influenza strains. The vaccine contained no preservatives and had a pH of 7.2 ± 0.5.
Study NCT00192413 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Inactivated Vaccine (TIV)
Description: Commercially available TIV, inactivated influenza vaccine (Split Virion) BP (Aventis Pasteur MSD, Lyon, France) was administered IM according to the manufacturer's dosing instructions (one 0.5-mL IM dose for adults).
Study NCT01018485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Intramuscular injection in affected limb up to 100 Units. Two doses (one placebo, one active) 3 months apart.
Study NCT03854513 — intervention group
Intervention type: DEVICE
Intervention: dialysis machine
Description: A machine used in dialysis that filters a patient's blood to remove excess water and waste products when the kidneys are damaged
Study NCT01413139 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 4F portfolio products from Biotronik
Description: 4F portfolio products from Biotronik: Astron pulsar / Astron Pulsar-18, Fortress, Passeo-18, Cruiser-18
Study NCT01281540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisapride
Description: one 10 mg tablet 4 times a day for 8 weeks
Study NCT01281540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one placebo tablet 4 times a day for 8 weeks
Study NCT03779048 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Treatment
Description: Behavioral treatment (BT) for weight loss includes diet and physical activity recommendations and behavior therapy strategies. All participants will complete an initial 4-week BT run-in, delivered in individual, 20-30 minute weekly sessions. After the end of the run-in, participants will be offered an additional 24 weeks of 20-30 minute individual BT sessions, occurring weekly for the first 12 weeks and every other week for the last 12 weeks (total of 18 visits).
Study NCT03779048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.
Study NCT03779048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine 15 MG
Description: The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.
Study NCT02503501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Study NCT02503501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Bacteriostatic 0.9% Sodium Chloride
Study NCT02211612 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PUFA-group
Study NCT02211612 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SFA-group
Study NCT03825211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous suture in the perineals lesions
Description: A continuous suture of the vagina, muscle and skin is performed continuously, without knotting or cutting the suture thread.
Study NCT03825211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Discontinuous suture in the perineals lesions
Description: Suture the muscle independently of the vagina and independently of the skin
Study NCT02008227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg IV infusion on Day 1 of each 21-day cycle
Study NCT02008227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m\^2 IV infusion on Day 1 of each 21-day cycle
Study NCT02825524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Habib™ EndoHBP
Description: During an endoscopic retrograde cholangiography, endobiliary application of radiofrequency through a dedicated probe named Habib.
Study NCT04139850 — intervention group
Intervention type: DRUG
Intervention: Discontinuation of antiviral treatment in chronic hepatitis B cohort patients
Description: For the selective patients in the cohort with long-term antiviral therapy and with conditions such as HBeAg negative or loss more than one year, antiviral therapy is able to be discontinued with an intensive inspection who agreed to the process. If there are need of this intervention, another multicenter IRB approval will be taken.
Study NCT00627367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Hydromorphone 1mg IV, followed by an optional dose of 1mg IV hydromorphone 15 minutes
Study NCT00627367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nonprotocolized
Description: An IV opioid the type and dose of which will be determined by the treating clinician
Study NCT00680459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 70% ethanol
Description: 70% ethanol lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. 70% ethanol solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
Study NCT00680459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: heparin flush solution
Description: heparin flush (10 units/ml) lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. Heparin lock solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
Study NCT04188704 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Interference screw
Description: Anterior cruciate ligament reconstruction (anterior screw fixation or posterior screw fixation)
Study NCT04188704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interference screw
Description: Anterior cruciate ligament reconstruction (anterior screw fixation or posterior screw fixation)
Study NCT02944786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOPE-model
Description: There are four sessions of person-centered health dialogues. The sessions also include pain/stress management and education about stress and pain (the HOPE model that is an adolescent-centered school health prevention program when adolescents have chronic pain).
Study NCT02290041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion of MSC
Description: Intravenous infusion of 4 doses of adipose tissue derived allogeneic adult mesenchymal stem cells (1 million MSCs/Kg, weeks 0-4-8-20).
Study NCT02290041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Infusion of placebo
Description: Infusion of placebo (weeks 0-4-8-20)
Study NCT01618695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Core study: 4 milligram (mg) group- Week 0 Once daily 2 milligram per day (mg/day), Week 1 to Week 18 Once daily 4 mg/day; 8 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 to Week 18 Once daily 8 mg/day; 12 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 Once daily 8 mg/day, Week 4 Once daily 10 mg/day, Week 5 to Week 18 Once daily 12 mg/day.~Extension study: 4 mg group- Week 19 to Week 22 Once daily 4 mg/day, Week 23 Once daily 6 mg/day, Week 24 Once daily 8 mg/day, Week 25 Once daily 10 mg/day, Week 26 to Week 75 or more Once daily 12 mg/day; 8 mg group- Week 19 to Week 22 Once daily 8 mg/day, Week 23 Once daily 10 mg/day, Week 24 to Week 75 or more Once daily 12 mg/day; 12 mg group- Week 19 to Week 75 or more Once daily 12 mg/day.
Study NCT01618695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Core study: Week 0 to Week 18 Once daily placebo.~Extension study:~Week 19 to Week 22 Once daily placebo, Week 23 Once daily perampanel 2 mg/day, Week 24 Once daily perampanel 4 mg/day, Week 25 Once daily perampanel 6 mg/day, Week 26 Once daily perampanel 8 mg/day, Week 27 Once daily perampanel 10 mg/day, Week 28 to Week 75 or more Once daily perampanel 12 mg/day.
Study NCT03833219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly feedback
Description: Send push notification reporting user's handheld phone use while driving compared to distribution for driver cohort (age, geographic area) each week.
Study NCT03833219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: End of intervention period incentive
Description: Notify participant about potential incentive at the end of the intervention period, but do not provide weekly feedback about performance.
Study NCT03833219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss-framed weekly incentive
Description: Send push notification reporting user's handheld phone use while driving compared to distribution for driver cohort (age, geographic area) each week. Pay participant weekly according to where they fall on the distribution each week.
Study NCT00866073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine 15 mg/m2 i.v.
Description: Decitabine at 15 mg/m2 i.v. x 3 hours, three times daily on three consecutive days
Study NCT04683367 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: laparoscopic repair of hernia
Study NCT02927028 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Chewing
Description: On the first visit, the random nut treatments will include chewing walnuts, almonds and pistachios. The chewing conditions will include: 1) 5 g nuts alone, 2) 5 g nuts with 5 ml water, 3) 5 g nuts with 5 ml apple juice, 4) 5 g nuts with 5 g plain yogurt, 5) 5 g nuts with 5 g sweet yogurt.~On visits 2 and 3 the treatments of either 28 g of walnuts or walnut butter will be presented.
Study NCT01438970 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ALFApump system
Description: The device described above will be implanted using general anaesthesia. The device will be programmed according to each patient's individual requirements, setting the daily loss of ascitic fluid needed to maintain a stable body weight.
Study NCT02627612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pro Vetus
Description: Volunteer mentors (a mix of Veterans and non-Veterans) in the civilian community work with transitioning Veterans for approximately four months within five transition domains (1. Employment/Education, 2. Housing, 3. Family and Legal, 4. Social/Community/ Physical Fitness and 5. Medical Care).
Study NCT02627612 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Team Red, White, and Blue (TM RWB)
Description: TM RWB is a 501(c)(3) non-profit, Veteran support organization found in 2010. Its mission is to enrich the lives of America's Veterans by connecting them to their community through physical and social activity. Central to TM RWB's mission is that inspiring Veterans to become physically active will create opportunities to establish authentic connections to other Veterans, active duty military, and civilians as well as improve the chances for continued successful integration. Enrollment in TM RWB takes place by simply signing up online and providing a name, email address, and zip code (teamrwb.org). TM RWB is not designed as a mental health intervention.
Study NCT02627612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team Red, White, and Blue (TM RWB)
Description: TM RWB is a 501(c)(3) non-profit, Veteran support organization found in 2010. Its mission is to enrich the lives of America's Veterans by connecting them to their community through physical and social activity. Central to TM RWB's mission is that inspiring Veterans to become physically active will create opportunities to establish authentic connections to other Veterans, active duty military, and civilians as well as improve the chances for continued successful integration. Enrollment in TM RWB takes place by simply signing up online and providing a name, email address, and zip code (teamrwb.org). TM RWB is not designed as a mental health intervention.
Study NCT00515307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cellular transplantation
Description: 600 million to 1 billion cells will be infused through the portal vein over 30 minutes. Infusion will be done one time.
Study NCT02227485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Punica granatum Pleniflora (Golnaar) mouth rinse
Description: All the patient in intervention group use 10 ml of Golnaar mouth rinse for 2 minutes every night for 2 weeks.